Recent Company News

• 09:31 AM ET Feb 24, 2026
  

  Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis

• 09:36 AM ET Feb 23, 2026
  

  StreetAccount Summary - Private company transactions for the week ended 21-Feb

• 03:05 AM ET Feb 23, 2026
  

  L'Oréal played key role in recent ouster of Sanofi CEO Paul Hudson and choice of his successor -- Bloomberg, citing sources (20-Feb, post EU market close) (€79.58, 0.00)

• 08:01 PM ET Feb 20, 2026
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 02:11 PM ET Feb 20, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 22-Feb

• 08:15 AM ET Feb 20, 2026
  

  StreetAccount Themes Headlines (20-Feb)

• 06:16 AM ET Feb 20, 2026
  

  EU Commission invests €225M to deliver next-generation influenza vaccines

• 02:46 PM ET Feb 19, 2026
  

  Follow-up: CDC ACIP meeting pushed into the middle of March

• 02:03 PM ET Feb 19, 2026
  

  US CDC reportedly postpones vaccine advisory committee meeting scheduled later this month - Reuters

• 09:07 PM ET Feb 17, 2026
  

  NICE recommends Regeneron's Dupixent to treat severe chronic rhinosinusitis with nasal polyps ($793.53, 0.00)